$NKTR: Nektar -5.9% as it reports urothelial cancer study

Date: Monday, February 11th, 2019

Stock(s) mentioned:

Source: Seeking Alpha (https://seekingalpha.com)

Summary: Nektar Therapeutics (NASDAQ:NKTR) is 5.9% lower postmarket after it reported a response rate of 48% in its study of treatment for urothelial cancer. That rate …

Full article address: https://seekingalpha.com/news/3431934-nektar-minus-5_9-percent-reports-urothelial-cancer-study

Related News:

$NKTR: Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin …

$NKTR: Nektar Therapeutics to Webcast Conference Call with Urothelial …

$NKTR: Why Nektar Therapeutics Stock Gained 29% in January

$BMY $NKTR: Is Bristol-Myers Squibb a Bargain Now?

$NKTR $BMY: Here’s Why Nektar Therapeutics Gave Back 45% in 2018

$NKTR $BMY: Here’s Why Nektar Therapeutics Surged Today

$NKTR: ImaginAb Announces Immuno-Oncology License and Clinical Trial …

$NKTR: Rosen Law Firm Reminds Nektar Therapeutics Investors of …

$AMD $NKTR: Stocks to Buy Before a Fed Rate Hike

$NKTR $LDOS: Nektar Therapeutics (NKTR): Are Hedge Funds Right About This …

$STLD $ARMK $NKTR: Here is What Hedge Funds Think About Steel Dynamics, Inc. (STLD)

Latest News:

$APHA $HAIN: Here’s What Investigators Just Said About Aphria

$XXII: Stull, Stull & Brody Launches Investigation into Possible Breaches of …

$AMZN $NVDA: Tech Stocks This Week: Amazon’s Acquisition, NVIDIA Earnings …

$MCD $SBUX: Why I’m Not Buying the Chipotle Comeback Yet

$PYPL $WU $V: 3 Top Fintech Stocks to Buy in February

$HPP: Hudson Pacific Properties Inc (HPP) CEO Victor Coleman on Q4 …

$CTL: Can CenturyLink Sustain Its New Dividend After Full-Year 2018 …

$CCJ: Is Denison Mines a Buy?

$BRK-A $BRK-B $DAL $AAL: Warren Buffett Just Sold These Stocks

$RUSHA: Rush Enterprises, Inc. (RUSHA) CEO Rusty Rush on Q4 2018 …

$MTRN: Materion Corp. (MTRN) CEO Jugal Vijayvargiya on Q4 2018 Results …